The Cognivue Amyloid Risk Measure (CARM): A Novel Method to Predict the Presence of Amyloid with Cognivue Clarity

Abstract Introduction At the present time, clinical detection of individuals who have amyloid in their brain is not possible without expensive biomarkers. The objective of the study was to test whether Cognivue Clarity® can differentiate True Controls, preclinical Alzheimer’s disease (pAD), mild cog...

Full description

Saved in:
Bibliographic Details
Main Authors: James E. Galvin, Michael J. Kleiman, Heather M. Harris, Paul W. Estes
Format: Article
Language:English
Published: Adis, Springer Healthcare 2025-04-01
Series:Neurology and Therapy
Subjects:
Online Access:https://doi.org/10.1007/s40120-025-00741-x
Tags: Add Tag
No Tags, Be the first to tag this record!